SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer revenue guidance, a reduced advertising outlook, and concerns about slowing growth, prompting analyst downgrades and price-target cuts. Traders are split between viewing the outlook and competition concerns as signs of a deeper growth problem and treating the selloff as an overreaction and buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro sharply raised its preliminary fiscal Q1 outlook on stronger AI-platform demand and improved gross-margin expectations, driving a rally. Traders largely welcomed the demand signal and speculated about a short squeeze, while skeptics questioned whether margins, cash flow and execution can sustain the move.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, including its first profit as a public company and rapid AI-compute growth, prompted a rally and a wave of analyst upgrades. Traders are broadly upbeat, while skeptics point to heavy capital spending and upcoming share unlocks; a possible Tesla merger is also being discussed but remains exploratory.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&Ts earnings beat and higher outlook failed to prevent a selloff, with traders pointing to postpaid phone additions falling short of expectations. The reaction is debated as either concern about subscriber momentum and lingering SpaceX competition or an overreaction to otherwise solid results, with some investors buying the dip.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention amid persistent share-price weakness despite community references to ORLADEYO growth and profitable results, fueling criticism of management and calls for buybacks or a sale. Some traders point to future navenibart and Netherton data and continued ORLADEYO growth as potential catalysts, while skeptics focus on dilution, debt and uncertainty around the companys acquisition-led strategy.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives preferred-stock offering and continued Bitcoin purchases are driving discussion, with bulls viewing the financing as fuel for treasury growth while skeptics warn that dilution and preferred-dividend obligations could weigh on common shareholders.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings have traders focused on Google Cloud growth and whether AI investments can generate returns, amid widespread concern about heavy capital spending and speculation it could rise further. The debate is split between dip-buyers citing Alphabets AI and cloud businesses and bearish traders worried about spending, search disruption, and the shares persistent weakness.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Early Phase 1 azer-cel findings in progressive MS are the main focus, with traders highlighting reported deep B-cell depletion and disability or MRI signals as a potential growth story beyond BRIUMVI. The reaction is broadly optimistic but tempered by the small, preliminary study and uncertainty about whether the data will translate into meaningful clinical benefit; some also note the stocks muted, choppy response.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

OpenAIs plan to offer its frontier models through Google Cloud, alongside new AI infrastructure plans, is drawing attention as traders weigh potential cloud growth against heavy spending and execution risks. The discussion is also focused on GOOGLs weak, range-bound trading ahead of earnings, with optimism about AI monetization competing with frustration over the stocks price action.

TOSHI

TOSHIs sharp rebound and rising trading activity have sparked breakout chatter, with traders watching a stubborn resistance level and speculating about a short squeeze. The bullish momentum is disputed by holders pointing to failed breakouts, weak price action and dependence on a broader crypto-market recovery; listing and announcement talk remains unconfirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know

Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totaling 411,325 shares, an increase of 477.3% from the March 31st total of 71,244 shares. Approximately 1.1% of the company's shares are...

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts

Shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are currently covering the stock, MarketBeat...

Analysts Offer Predictions for Adagene FY2026 Earnings

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Adagene in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.37) per share fo...

Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price

Guggenheim raised their price target on Adagene from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday...

Why Is ADAG Stock Tanking Today?

Equity

Adagene priced the public offering of its American depository shares at $3.75 per ADS, representing a discount of nearly 19% from ADAG’s closing price on Wednesday.

Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS

Adagene (NASDAQ:ADAG - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28...

Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6%

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 74,016...

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are currently covering the company, Marketbeat reports. One...

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Adagene Inc - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Adagene also announced an update from the Phase 1b/2 study of Muzastotug in combination with Keytruda in patients with Microsatellite Stable Colorectal Cancer with no liver metastases.</li><li>The company stated that the results show an improved durability of response among patients in the trials.</li><li>Adagene added that Muzastotug, in combination with Merck’s Keytruda, has received Fast Track designation from the FDA.</li></ul>Adagene Inc. (ADAG) shares tanked nearly 10% in Thursday’s opening trade after the company announced a slew of updates, including the pricing of a $70 million public offering of its American depository shares.Adagene priced the public offering at $3.75 per ADS, representing a discount of nearly 19% from ADAG’s closing price on Wednesday. The offering is expected to close on April 6, 2026.Adagene also announced an update from the Phase 1b/2 study of Muzastotug in Combination with Keytruda in patients with Microsatellite Stable Colorectal Cancer (MSS CRC) with no liver metastases. The company stated that the results show an improved durability of response among patients in the trials.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ADAG">Adagene</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Adagene Provides Update On Muzastotug Trials</h2>The company stated that Muzastotug, in combination with Merck’s Keytruda, achieved an overall response rate (ORR) of 31% in the combined 20 mg/kg dose cohort, compared to an ORR of 13% in the 10 mg/kg dose cohort.Adagene added that the median duration of response (mDOR) has not yet been achieved in the 20 mg/kg dose cohort, with responses ongoing beyond 9 months. However, the 10 mg/kg dose cohort achieved an mDOR of 6.2 months.The Progression-Free Survival (PFS) stood at 6.7 months in the 20 mg/kg cohort, outlasting the 4.8 months observed in the 10 mg/kg dose cohort, according to the company.Adagene stated that Muzastotug, in combination with Merck’s Keytruda, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).In the 10 mg/kg cohort, the median overall survival was 19.8 months, with 48% of patients alive at two years. In the 20 mg/kg cohort, one-year survival was 80.8%, compared with 70.1% in the 10 mg/kg cohort.The company added that there was a 4% discontinuation rate across the two doses, and that there were no dose-limiting toxicities observed.<h2 class="st-heading-2">Adagene Teams Up With Incyte</h2>Adagene stated that it has partnered with Incyte Corp. (INCY) to evaluate the combination of muzastotug and INCA33890 in patients with MSS CRC with or without liver metastases.The company added that as a monotherapy, INCA33890 has demonstrated promising clinical efficacy and safety in immune checkpoint sensitive and insensitive cancers, including MSS CRC with and without liver metastases.<a href="https://stocktwits.com/symbol/ADAG">ADAG stock</a> is up 130% year-to-date. The Invesco Golden Dragon China ETF (PGJ) is down 14% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-march-2026/cZ7xoOYRI8R">Tesla’s China-Made EV Sales Rise 9% In March, Registering Fifth Straight Month Of Gains: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Invesco Golden Dragon China ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.47
Prev Close	$2.50
Open	$2.47
Dividend Yield	0.00%
50-Day Moving Average	$3.27
Beta	0.26
Avg. Volume	254,066.98
PE Ratio	-6.63

52-Week High	$4.85
52-Week Low	$1.30
Market Capitalization	$167.86M
EPS (Annual)	-$0.374
Price to Book	1.88
Revenue Per Employee	$60,087.42

Feed

News

Sentiment

Fundamentals

Info

ADAG Fundamentals